BDR Pharmaceuticals unveiled Zisavel Capsules, a generic antifungal drug for treating invasive aspergillosis and mucormycosis. Zisavel, an isavuconazole derivative, crucially treats invasive aspergillosis. These 100 mg capsules, priced at ₹7,992 for a pack of seven, represent a fraction of the cost of the current therapy by Innovators, targeting primary treatment for these fungal infections. BDR Pharmaceuticals aims to render isavuconazole therapy as affordable as voriconazole and posaconazole, thus ensuring accessibility for financially challenged patients.

With 140 cases per million, India has a much higher prevalence of mucormycosis than developed countries. In 2020, invasive aspergillosis was responsible for approximately 2,360 deaths.

The global market for antifungal drugs was worth $15.8 billion in 2022, and it is expected to grow at a 3.74 percent CAGR between 2023 and 2030. This expansion is primarily driven by the rising prevalence of fungal infections such as aspergillosis and candidiasis.

The Indian antifungal drugs market, estimated to be worth $1.56273 billion in 2021, is expected to grow at a 10.49 percent CAGR until 2030.

Raheel Shah, Director of Business Development at BDR Group, said, “This drug, available at 1/3 the innovator brand price, will enhance infection control and life expectancy.”

He added, “Access to affordable healthcare is a fundamental right. We’ll work tirelessly to ensure our mucormycosis drug reaches those in need.”